 |
인쇄하기
취소
|
GSK’s new beta-blocker to be released in domestic hypertensive drug market
A new beta-blocker, Nebilet (nebivolol), will join the arsenal of drugs available to treat hypertension, according to GlaxoSmithKline (GSK)
Holding the launching symposium, GSK has signed an agreement with Italy based Mylan Laboratories to distribute Nebilet in Korea.
Nebivolol is a selective beta-1-blocker and has the added pharmacological properties of producing vasodilation and reducin...
Holding the launching symposium, GSK has signed an agreement with Italy based Mylan Laboratories to distribute Nebilet in Korea.
Nebivolol is a selective beta-1-blocker and has the added pharmacological properties of producing vasodilation and reducin...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.